Avadel Pharmaceuticals plc (AVDL)
NASDAQ: AVDL · Real-Time Price · USD
13.00
-0.22 (-1.66%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Avadel Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 95.15 | 27.96 | - | - | 22.33 | 59.22 | Upgrade
|
| Revenue Growth (YoY) | 6260.23% | - | - | - | -62.28% | -42.66% | Upgrade
|
| Cost of Revenue | 5.12 | 0.85 | - | - | 5.74 | 12.13 | Upgrade
|
| Gross Profit | 90.03 | 27.12 | - | - | 16.59 | 47.09 | Upgrade
|
| Selling, General & Admin | 176.49 | 151.71 | 74.52 | 68.5 | 32.41 | 30.18 | Upgrade
|
| Research & Development | 12.33 | 13.26 | 20.7 | 17.1 | 20.44 | 32.92 | Upgrade
|
| Operating Expenses | 188.82 | 164.97 | 95.22 | 85.6 | 53.25 | 63.92 | Upgrade
|
| Operating Income | -98.79 | -137.85 | -95.22 | -85.6 | -36.66 | -16.83 | Upgrade
|
| Interest Expense | -9.64 | -9.89 | -12.34 | -9.94 | -12.99 | -12.48 | Upgrade
|
| Interest & Investment Income | 2.47 | 1.89 | 1.22 | 2.44 | 0.41 | 0.74 | Upgrade
|
| EBT Excluding Unusual Items | -105.96 | -145.85 | -106.34 | -93.1 | -49.25 | -28.57 | Upgrade
|
| Merger & Restructuring Charges | - | - | -3.35 | 0.05 | 0.04 | -6.44 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.7 | -1.8 | -1.75 | -0.1 | -0.44 | 0.33 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 45.76 | -2.68 | Upgrade
|
| Legal Settlements | - | - | - | - | -0.8 | - | Upgrade
|
| Other Unusual Items | - | -13.13 | - | - | -0.4 | -1.22 | Upgrade
|
| Pretax Income | -106.65 | -160.78 | -111.44 | -93.15 | -5.08 | -38.58 | Upgrade
|
| Income Tax Expense | -0.43 | -0.5 | 26.03 | -15.82 | -12.11 | -5.36 | Upgrade
|
| Earnings From Continuing Operations | -106.22 | -160.28 | -137.46 | -77.33 | 7.03 | -33.23 | Upgrade
|
| Net Income | -106.22 | -160.28 | -137.46 | -77.33 | 7.03 | -33.23 | Upgrade
|
| Net Income to Common | -106.22 | -160.28 | -137.46 | -77.33 | 7.03 | -33.23 | Upgrade
|
| Shares Outstanding (Basic) | 92 | 80 | 60 | 59 | 53 | 37 | Upgrade
|
| Shares Outstanding (Diluted) | 92 | 80 | 60 | 59 | 55 | 37 | Upgrade
|
| Shares Change (YoY) | 39.29% | 33.41% | 2.66% | 6.54% | 46.89% | 0.21% | Upgrade
|
| EPS (Basic) | -1.16 | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | Upgrade
|
| EPS (Diluted) | -1.16 | -2.00 | -2.29 | -1.32 | 0.13 | -0.89 | Upgrade
|
| Free Cash Flow | -114.15 | -128.51 | -71.02 | -77.34 | -48.83 | -38.35 | Upgrade
|
| Free Cash Flow Per Share | -1.24 | -1.60 | -1.18 | -1.32 | -0.89 | -1.03 | Upgrade
|
| Gross Margin | 94.62% | 96.97% | - | - | 74.29% | 79.52% | Upgrade
|
| Operating Margin | -103.82% | -492.97% | - | - | -164.15% | -28.42% | Upgrade
|
| Profit Margin | -111.64% | -573.17% | - | - | 31.47% | -56.11% | Upgrade
|
| Free Cash Flow Margin | -119.96% | -459.58% | - | - | -218.64% | -64.77% | Upgrade
|
| EBITDA | -97.23 | -136.08 | -93.72 | -84.78 | -34.97 | -14.34 | Upgrade
|
| EBITDA Margin | -102.19% | - | - | - | -156.58% | -24.22% | Upgrade
|
| D&A For EBITDA | 1.56 | 1.77 | 1.49 | 0.82 | 1.69 | 2.49 | Upgrade
|
| EBIT | -98.79 | -137.85 | -95.22 | -85.6 | -36.66 | -16.83 | Upgrade
|
| EBIT Margin | -103.82% | - | - | - | -164.15% | -28.42% | Upgrade
|
| Advertising Expenses | - | - | - | - | 0.31 | 0.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.